Stereotactic radiotherapy for oligometastatic cancer

Author(s): Dr Emma Doyle, Dr Iain Phillips, Donna Burns

Hospital: Edinburgh Cancer Centre, University of Edinburgh

Reference: RAD Magazine, 49, 579, 12-13


Patients diagnosed with metastatic cancer are living longer due to advances in both systemic anti-cancer therapies and radiotherapy. Metastases from primary tumours cause morbidity and it is estimated that metastases are responsible for approximately 90% of all cancer deaths.

The concept of oligometastatic disease (OMD) was first proposed in a seminal paper in 1995 by Hellman and Weichselbum. They described an intermediate state between localised cancer and widespread metastatic disease.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more